TriangleNCT05673785 · OUTCOME
CR Rate by IRF Per 2014 Lugano Classification
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- percentage of participants
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Up to approximately 7 months
What was measured
CR rate by IRF per 2014 Lugano Classification, assessed by integrated CT and PET-based responses was defined as the percentage of participants who achieved a CR by IRF following the completion of study treatment. CR was defined as disappearance of all evidence of disease.
Analysis population: The FAS consisted of all enrolled participants.
Groups in this outcome
Brentuximab Vedotin + CHP
Participants received brentuximab vedotin 1.8 mg/kg, IV infusion, within 1 hour of completing treatment with other IV agents, i.e., cyclophosphamide 750 mg/m\^2 and doxorubicin 50 mg/m\^2, on Day 1 of each 21-day cycle, and prednisone tablets, 100 mg daily, orally, on Days 1 through 5, for up to 8 cycles (6 months) or until PD, unacceptable toxicity, whichever occurred first.
| Group | Source count |
|---|---|
| Brentuximab Vedotin + CHP | 52 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Brentuximab Vedotin + CHP | 76.9 | Not reported | 63.2 | 87.5 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 63.2
- upper Limit
- 87.5
- value
- 76.9
- denoms
- counts
- group Id
- OG000
- value
- 52
- units
- Participants
- description
- CR rate by IRF per 2014 Lugano Classification, assessed by integrated CT and PET-based responses was defined as the percentage of participants who achieved a CR by IRF following the completion of study treatment. CR was defined as disappearance of all evidence of disease.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Participants received brentuximab vedotin 1.8 mg/kg, IV infusion, within 1 hour of completing treatment with other IV agents, i.e., cyclophosphamide 750 mg/m\^2 and doxorubicin 50 mg/m\^2, on Day 1 of each 21-day cycle, and prednisone tablets, 100 mg daily, orally, on Days 1 through 5, for up to 8 cycles (6 months) or until PD, unacceptable toxicity, whichever occurred first.
- id
- OG000
- title
- Brentuximab Vedotin + CHP
- param Type
- NUMBER
- population Description
- The FAS consisted of all enrolled participants.
- reporting Status
- POSTED
- time Frame
- Up to approximately 7 months
- title
- CR Rate by IRF Per 2014 Lugano Classification
- type
- SECONDARY
- unit Of Measure
- percentage of participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice